United States - English - NLM (National Library of Medicine)

cardinal health - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 200 ug - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol tablet has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol tablets should be taken for the duration of nsaid therapy. misoprostol tablets has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings . misoprostol tablets should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol tablets should not be taken by anyone with a history of all

United States - English - NLM (National Library of Medicine)

american health packaging - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 100 ug - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol tablet has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol tablets should be taken for the duration of nsaid therapy. misoprostol tablets has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings . misoprostol tablets should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol tablets should not be taken by anyone with a history of allergy to pr

United States - English - NLM (National Library of Medicine)

pharmacist pharmaceutical, llc - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 200 ug - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol tablet has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol tablets should be taken for the duration of nsaid therapy. misoprostol tablets has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol tablets should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol tablets should not be taken by anyone with a history of allergy to prosta

United States - English - NLM (National Library of Medicine)

apotheca inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 200 ug - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 200 ug - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

United States - English - NLM (National Library of Medicine)

greenstone llc - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 100 ug - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 100 ug - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, eg, the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

United States - English - NLM (National Library of Medicine)

genbiopro, inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - two 12-week, randomized, double-blind trials in osteoarthritic patients who had gastrointestinal symptoms but no ulcer on endoscopy while taking an nsaid compared the ability of 200 mcg of misoprostol tablets, 100 mcg of misoprostol tablets, and placebo to reduce the risk of gastric ulcer (gu) formation. patients were approximately equally divided between ibuprofen, piroxicam, and naproxen, and continued this treatment throughout the 12 weeks. the 200-mcg dose caused a marked, statistically significant reduction in gastric ulcers in both studies. the lower dose was somewhat less effective, with a significant result in only one of the studies. reduction of risk of gastric ulcers induced by ibuprofen, piroxicam, or naproxen [no. of patients with ulcer(s) (%)] in these trials there were no significant differences between misoprostol tablets and placebo in relief of day or night abdominal pain. no effect of misoprostol tablets in reducing the risk of duodenal ulcers was demonstrated, but relatively few duodenal lesions were seen. in another clinical trial, 239 patients receiving aspirin 650 to 1300 mg q.i.d. for rheumatoid arthritis who had endoscopic evidence of duodenal and/or gastric inflammation were randomized to misoprostol 200 mcg q.i.d. or placebo for 8 weeks while continuing to receive aspirin. the study evaluated the possible interference of misoprostol tablets on the efficacy of aspirin in these patients with rheumatoid arthritis by analyzing joint tenderness, joint swelling, physician's clinical assessment, patient's assessment, change in ara classification, change in handgrip strength, change in duration of morning stiffness, patient's assessment of pain at rest, movement, interference with daily activity, and esr. misoprostol tablets did not interfere with the efficacy of aspirin in these patients with rheumatoid arthritis. misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol tablet has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol tablets should be taken for the duration of nsaid therapy. misoprostol tablets has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings . misoprostol tablets should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol tablets should not be taken by anyone with a history of allergy to prostaglandins.

United States - English - NLM (National Library of Medicine)

dash pharmaceuticals llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac sodium and misoprostol delayed-release tablets and other treatment options before deciding to use diclofenac sodium and misoprostol delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. see warnings, gastrointestinal effects - risk of ulceration, bleeding and perforation for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications. see boxed contraindications and warnings related to misoprostol. diclofenac sodium and misoprostol delayed-release tablets should not be taken by pregnant women. diclofenac sodium and misoprostol delayed-releas

United States - English - NLM (National Library of Medicine)

eagle pharmaceuticals, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac sodium and misoprostol delayed-release tablets and other treatment options before deciding to use diclofenac sodium and misoprostol delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. see warnings, gastrointestinal effects - risk of ulceration, bleeding and perforation for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications. see boxed contraindications and warnings related to misoprostol. diclofenac sodium and misoprostol delayed-release tablets should not be taken by pregnant women. diclofenac sodium and misoprostol delayed-releas